A number of firms have modified their ratings and price targets on shares of UnitedHealth Group (NYSE: UNH) recently:

  • 10/24/2017 – UnitedHealth Group had its “buy” rating reaffirmed by analysts at Mizuho. They wrote, “3Q17 adjusted cash EPS of $1.90, up 9.3% y/y, was $0.02 below our estimate of $1.92, but inline with consensus. GAAP EPS of $1.46, up 27.0% y/y, was above our estimate of $1.44, but below consensus of $1.49. The company slightly raised the lower end of its 2017 adjusted EPS guidance to $6.97-$7.05, from $6.95-$7.05, bracketing both our estimate of $7.00 and consensus of $6.99. ESRX appointed former interim CFO James Havel (January 2015-September 2015) as its CFO. He replaces Eric Slusser, who had served as CFO since September 2015.””
  • 10/19/2017 – UnitedHealth Group had its “outperform” rating reaffirmed by analysts at Sanford C. Bernstein. They now have a $219.00 price target on the stock, up previously from $210.00.
  • 10/19/2017 – UnitedHealth Group had its price target raised by analysts at Argus from $215.00 to $230.00. They now have a “buy” rating on the stock.
  • 10/18/2017 – UnitedHealth Group had its price target raised by analysts at Cantor Fitzgerald to $225.00. They now have an “overweight” rating on the stock.
  • 10/18/2017 – UnitedHealth Group had its “buy” rating reaffirmed by analysts at Leerink Swann. They now have a $240.00 price target on the stock, up previously from $225.00.
  • 10/18/2017 – UnitedHealth Group had its price target raised by analysts at Morgan Stanley from $215.00 to $235.00. They now have an “overweight” rating on the stock.
  • 10/18/2017 – UnitedHealth Group had its price target raised by analysts at Citigroup Inc. from $213.00 to $235.00. They now have a “buy” rating on the stock.
  • 10/18/2017 – UnitedHealth Group had its price target raised by analysts at Bank of America Corporation from $230.00 to $240.00. They now have a “buy” rating on the stock.
  • 10/18/2017 – UnitedHealth Group had its price target raised by analysts at Oppenheimer Holdings, Inc. from $215.00 to $205.00. They now have an “outperform” rating on the stock.
  • 10/17/2017 – UnitedHealth Group had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $208.00 price target on the stock.
  • 10/17/2017 – UnitedHealth Group had its price target raised by analysts at Piper Jaffray Companies to $228.00. They now have an “overweight” rating on the stock.
  • 10/16/2017 – UnitedHealth Group is now covered by analysts at BMO Capital Markets. They set an “outperform” rating and a $250.00 price target on the stock.
  • 10/13/2017 – UnitedHealth Group had its price target raised by analysts at Jefferies Group LLC from $215.00 to $225.00. They now have a “buy” rating on the stock.
  • 10/10/2017 – UnitedHealth Group had its “outperform” rating reaffirmed by analysts at Sanford C. Bernstein. They now have a $210.00 price target on the stock.
  • 10/10/2017 – UnitedHealth Group was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Shares of UnitedHealth Group has outperformed the industry in last one year. Its  robust Government business and continued strong growth at Optum are driving long-term growth. Its international business, growing membership and strong capital position are the other positives. In the most recently reported quarter, the company reported better-than-expected earnings, driven by an increase in revenues and membership. Encouraged by its impressive first-half earnings, the company raised the 2017 guidance. Nevertheless, the company has reduced its exposure to the troubled public exchange business. Though this move will shield it from losses in this business, premium revenues are likely to be affected. Charges related to Penn Treaty are also causes for concern.”
  • 10/5/2017 – UnitedHealth Group was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 9/26/2017 – UnitedHealth Group was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Shares of UnitedHealth Group has outperformed the industry in last one year. Its  robust Government business and continued strong growth at Optum are driving long-term growth. Its international business, growing membership and strong capital position are the other positives. In the most recently reported quarter, the company reported better-than-expected earnings, driven by an increase in revenues and membership. Encouraged by its impressive first-half earnings, the company raised the 2017 guidance.”
  • 9/21/2017 – UnitedHealth Group was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $219.00 price target on the stock. According to Zacks, “Shares of UnitedHealth Group has outperformed the industry in last one year. Its  robust Government business and continued strong growth at Optum are driving long-term growth. Its international business, growing membership and strong capital position are the other positives. In the most recently reported quarter, the company reported better-than-expected earnings, driven by an increase in revenues and membership. Encouraged by its impressive first-half earnings, the company raised the 2017 guidance.”

UnitedHealth Group Incorporated (NYSE:UNH) traded up 0.25% on Wednesday, hitting $210.75. The company’s stock had a trading volume of 388,004 shares. The company has a market capitalization of $208.43 billion, a P/E ratio of 23.93 and a beta of 0.63. The company has a 50 day moving average price of $199.47 and a 200-day moving average price of $188.28. UnitedHealth Group Incorporated has a 1-year low of $136.22 and a 1-year high of $212.77.

UnitedHealth Group (NYSE:UNH) last released its quarterly earnings results on Tuesday, October 17th. The healthcare conglomerate reported $2.66 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.57 by $0.09. UnitedHealth Group had a net margin of 4.50% and a return on equity of 21.52%. The business had revenue of $50.32 billion for the quarter, compared to analysts’ expectations of $50.38 billion. During the same period in the prior year, the firm earned $2.17 earnings per share. UnitedHealth Group’s revenue was up 8.7% compared to the same quarter last year. On average, equities analysts forecast that UnitedHealth Group Incorporated will post $9.99 earnings per share for the current fiscal year.

In related news, Director William C. Ballard, Jr. sold 5,000 shares of the stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $193.98, for a total value of $969,900.00. Following the transaction, the director now directly owns 76,058 shares in the company, valued at $14,753,730.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Richard T. Burke sold 15,000 shares of the stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $191.71, for a total transaction of $2,875,650.00. Following the completion of the transaction, the director now owns 1,818,898 shares in the company, valued at $348,700,935.58. The disclosure for this sale can be found here. Insiders have sold 77,149 shares of company stock worth $15,182,242 over the last three months. 0.89% of the stock is owned by insiders.

UnitedHealth Group Incorporated is a health and well-being company. The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. It conducts its operations through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.

Receive News & Ratings for UnitedHealth Group Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.